Email this article The evaluation of minimal disseminated disease in the bone marrow of children with Burkitt lymphoma using next generation sequencing
- Authors: Volchkov E.V.1,2, Abugova Y.G.1, Mamedov I.Z.3, Abramov D.S.1, Senchenko M.A.1, Anderzhanova L.K.1, Komkov A.Y.3, Fominykh V.V.1, Olshanskaya Y.V.1, Myakova N.V.1, Novichkova G.A.1
-
Affiliations:
- The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
- The Research Institute of Molecular and Cellular Medicine, Рeoples’ Friendship University of Russia
- The Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
- Issue: Vol 22, No 1 (2023)
- Pages: 32-38
- Section: ORIGINAL ARTICLES
- Submitted: 18.11.2022
- Accepted: 27.02.2023
- Published: 14.02.2023
- URL: https://hemoncim.com/jour/article/view/693
- DOI: https://doi.org/10.24287/1726-1708-2023-22-1-32-38
- ID: 693
Cite item
Full Text
Abstract
The effectiveness of treatment for children with B-cell non-Hodgkin lymphomas (B-NHL) has reached 85–90% after the introduction of modern risk-adapted treatment regimens that involve risk group stratification based on tumor stage. Bone marrow involvement is traditionally evaluated using quantitative morphological analysis of tumor cells which has, however, a lower sensitivity compared to molecular genetic methods. In our study, we used next generation sequencing (NGS) to identify tumor-specific V-(D)/J-rearrangements of immunoglobulin genes which can be used as a marker for the evaluation of minimal disseminated disease (MDD) in children with B-NHL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Here we demonstrated that NGS allows detection of bone marrow involvement at a sensitivity of 10–6 in patients with Burkitt lymphoma, in whom standard morphological analysis failed to reveal the presence of tumor cells. The detection of molecular MDD can improve tumor staging and risk stratification in children with B-cell non-Hodgkin lymphomas.
About the authors
E. V. Volchkov
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation;The Research Institute of Molecular and Cellular Medicine, Рeoples’ Friendship University of Russia
Author for correspondence.
Email: volchcov.egor@yandex.ru
ORCID iD: 0000-0002-2574-1636
Egor V. Volchcov, a hematologist at the Lymphoma Research Department
1 Samory Mashela St., Moscow 117997, Russia
Russian FederationYu. G. Abugova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
Moscow
Russian FederationI. Z. Mamedov
The Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Moscow
Russian FederationD. S. Abramov
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
Moscow
Russian FederationM. A. Senchenko
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
Moscow
Russian FederationL. Kh. Anderzhanova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
Moscow
Russian FederationA. Yu. Komkov
The Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Moscow
Russian FederationV. V. Fominykh
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
Moscow
Russian FederationYu. V. Olshanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
ORCID iD: 0000-0002-2352-7716
Moscow
Russian FederationN. V. Myakova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
ORCID iD: 0000-0002-4779-1896
Moscow
Russian FederationG. A. Novichkova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation
ORCID iD: 0000-0002-2322-5734
Moscow
Russian FederationReferences
Supplementary files
